β2-adrenergic receptor gene polymorphism is associated with mortality in septic shock

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 2, 2010, Pages 143-149

  Nakada, Taka Aki ^a   Russell, James A ^a   Boyd, John H ^a   Aguirre Hernandez, Rosalia ^a   Thain, Katherine R ^a   Thair, Simone A ^a   Nakada, Emiri ^a   McConechy, Melissa ^a   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Genetic association study; Lymphoblastoid cells; Septic shock; Single nucleotide polymorphisms

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYSTEINE; GLUTAMINE; GLYCINE; HYDROCORTISONE; INTERLEUKIN 6; NORADRENALIN; NORADRENALIN BITARTRATE; SALBUTAMOL; SALBUTAMOL SULFATE; STEROID; VASOPRESSIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ADULT; AGED; ALLELE; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART RATE; HOMOZYGOTE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RECEPTOR GENE; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; CANADA; CELL CULTURE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; INFANT; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; ALLELES; BRITISH COLUMBIA; CELLS, CULTURED; CHILD; COHORT STUDIES; DOUBLE-BLIND METHOD; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; INFANT; INTERLEUKIN-6; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; NOREPINEPHRINE; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 74949089131     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200903-0332OC     Document Type: Article

References (37)

1. Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J 2007;7:29-37.
2. Brodde OE. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 2008;22:107-125.
3. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-1512.
4. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-9419.
5. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998;102:1927-1932.
6. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001;345:1030-1035.
7. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483-10488.
8. Oostendorp J, Postma DS, Volders H, Jongepier H, Kauffman HF, Boezen HM, Meyers DA, Bleecker ER, Nelemans SA, Zaagsma J, et al. Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes. Am J Respir Crit Care Med 2005;172:322-328.
9. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters SP, Weiss ST, Bleecker ER. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006;174:1101-1109.
10. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-1250.
11. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
12. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003;124:1103-1115.
13. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms and sepsis. Shock 2005;24:300-312.
14. Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007;35:12-17.
15. Bunker-Wiersma HE, Koopmans RP, Kuipers TW, Knoester H, Bos AP. Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection. Pediatr Crit Care Med 2008;9:517-523.
16. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
17. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 2003;33:422-425.
18. Mizuno K, Takahashi HK, Iwagaki H, Katsuno G, Kamurul HA, Ohtani S, Mori S, Yoshino T, Nishibori M, Tanaka N. Beta2-adrenergic receptor stimulation inhibits LPS-induced IL-18 and IL-12 production in monocytes. Immunol Lett 2005;101:168-172.
19. Malfait AM, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, FeldmannM. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol 1999;162:6278-6283.
20. Liu S, Stolz DB, Sappington PL, Macias CA, Killeen ME, Tenhunen JJ, Delude RL, Fink MP. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol 2006;290:C990-C999.
21. Farley KS, Wang L, Mehta S. Septic pulmonary microvascular endothelial cell injury: role of alveolar macrophage NADPH oxidase. Am J Physiol Lung Cell Mol Physiol 2009;296:L480-L488.
22. Taylor DR, Hall IP. ADRB2 polymorphisms and beta2 agonists. Lancet 2007;370:2075-2076.
23. Yu XY, Lin SG, Wang XM, Liu Y, Zhang B, Lin QX, Yang M, Zhou SF. Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clin Pharmacol Ther 2007;81:654-658.
24. + T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001;53:487-525.
25. van der Poll T, Jansen J, Endert E, Sauerwein HP, van Deventer SJ. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994;62:2046-2050.
26. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, Newton R, Giembycz MA. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 2008;295:L505-L514.
27. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-690.
28. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93:896-906.
29. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005;294:1526-1533.
30. Wilk JB, Myers RH, Pankow JS, Hunt SC, Leppert MF, Freedman BI, Province MA, Ellison RC. Adrenergic receptor polymorphisms associated with resting heart rate: the hypergen study. Ann Hum Genet 2006;70:566-573.
31. Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun 2002;16:290-332.
32. Bernardin G, Kisoka RL, Delporte C, Robberecht P, Vincent JL. Impairment of beta-adrenergic signaling in healthy peripheral blood mononuclear cells exposed to serum from patients with septic shock: involvement of the inhibitory pathway of adenylyl cyclase stimulation. Shock 2003;19:108-112.
33. Nakamura A, Imaizumi A, Yanagawa Y, Kohsaka T, Johns EJ. Beta(2)-adrenoceptor activation attenuates endotoxin-induced acute renal failure. J Am Soc Nephrol 2004;15:316-325.
34. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-1010.
35. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005;172:704-712.
36. Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clin Rev Allergy Immunol 2006;31:231-246.
37. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005;17:230-236.